The prostate is a walnut-sized gland below the bladder that produces seminal fluid. Prostate cancer arises from the glandular cells of the prostate and is the most common non-skin cancer in American men — and the second leading cause of cancer death in men after lung cancer.
Prostate cancer has a wide spectrum of behavior, from indolent, slow-growing tumors that may never cause harm to aggressive cancers that spread quickly if untreated. This biological heterogeneity — more than any other factor — is why prostate cancer management requires careful, individualized decision-making rather than a single treatment algorithm.
The overwhelming majority of prostate cancers (more than 95%) are adenocarcinomas — cancers arising from the secretory glandular cells. Rare variants include small cell carcinoma, ductal adenocarcinoma, and neuroendocrine prostate cancer, which can behave very differently and may arise de novo or as a transformation from adenocarcinoma after prolonged androgen deprivation therapy.
New U.S. cases/year
Deaths/year (2nd leading cancer death in men)
Lifetime risk for U.S. men
Lifetime risk for Black men
Several well-established factors increase a man’s likelihood of developing prostate cancer. Understanding your personal risk profile helps determine when to start screening and how frequently to monitor PSA.
Risk rises sharply after age 50. More than 60% of prostate cancers are diagnosed in men over 65. Younger men can develop it, particularly with genetic predisposition.
Black men have a 70% higher incidence and are twice as likely to die from prostate cancer compared to white men. Asian men generally have the lowest incidence. These disparities reflect both genetic and access-to-care factors.
Having a father or brother with prostate cancer roughly doubles a man's risk. Multiple affected first-degree relatives increases risk further, especially when diagnosed at younger ages.
BRCA2 mutations increase lifetime risk 5–8-fold and are associated with more aggressive disease. BRCA1, ATM, CHEK2, HOXB13, and Lynch syndrome (MMR gene) mutations also elevate risk. Germline testing is recommended for high-risk men and those with metastatic disease.
A diet high in red meat and saturated fat and low in vegetables may modestly increase risk. Obesity is associated with higher-grade disease and worse outcomes. Regular exercise appears protective.
Prostate cancer is more common in North America, Northern Europe, and Australia than in Asia and parts of Africa. Migration studies suggest environmental and dietary factors, not genetics alone, explain much of this variation.
Early prostate cancer — the most curable stage — typically causes no symptoms at all. This is why PSA screening exists: to detect cancer before symptoms develop. When symptoms do appear, they often overlap with those of benign prostatic hyperplasia (BPH) and should prompt evaluation rather than assumption.
Difficulty starting urination, weak stream, incomplete emptying, or increased urinary frequency — especially at night. More commonly caused by BPH than cancer, but warrant evaluation.
Hematuria or hematospermia. Uncommon in early disease; more common with locally advanced tumors involving the urethra or seminal vesicles.
Can be associated with locally advanced cancer involving the neurovascular bundles, but is much more commonly caused by other factors.
Deep, persistent pain in the hips, lower back, or pelvis — a hallmark symptom of metastatic prostate cancer spreading to bone, the most common site of distant spread.
Systemic symptoms suggesting advanced or metastatic disease; uncommon at presentation
Pelvic lymph node involvement or spinal cord compression from bone metastases can cause lower extremity edema, weakness, or neurological symptoms.
Many early bladder cancers cause no pain at all — blood in the urine is frequently the only warning sign, and it's often painless, which leads people to put off getting it checked. Any unexplained blood in the urine — even a single episode — deserves a prompt evaluation. Contact us if this applies to you.
Prostate cancer screening is one of the most nuanced and debated topics in oncology — not because screening doesn’t work, but because the benefits and harms must be weighed carefully for each individual. The goal is to find clinically significant cancers early, while avoiding unnecessary treatment of cancers that would never cause harm.
Discuss PSA screening starting at age 50. Shared decision-making between patient and physician weighs the benefits of early detection against the risk of overdiagnosis and overtreatment.
Discuss screening starting at age 40–45. Higher baseline risk means the benefit-to-harm ratio of screening is more favorable in these groups.
Consider initiating screening at age 40, with annual PSA testing. BRCA2-associated prostate cancer tends to be more aggressive and warrants earlier, more intensive surveillance.
Prostate-Specific Antigen (PSA) is a protein produced by both normal and cancerous prostate cells. A serum PSA above 4 ng/mL has traditionally been used as a threshold, but this is an oversimplification:
PSA can be elevated by benign conditions including BPH, prostatitis, urinary tract infections, recent ejaculation, digital rectal exam, and prostate biopsy — not only cancer. Conversely, some high-grade cancers can be present with PSA in the "normal" range. PSA velocity (rate of rise), PSA density (PSA relative to prostate volume), and PSA kinetics over time provide more nuanced information than a single value.
A DRE allows palpation of the posterior prostate surface. Abnormalities — firmness, nodularity, asymmetry — can indicate cancer even when PSA is normal and warrant further evaluation with MRI and/or biopsy. DRE is typically performed alongside PSA measurement.
An elevated or rising PSA, or an abnormal DRE, triggers a diagnostic workup that typically involves prostate MRI followed by biopsy when indicated. Modern prostate cancer diagnosis at Bansal Urology is MRI-guided and precision-targeted — not the older systematic 12-core approach that missed significant cancers and over-detected low-risk ones.
The first step in the modern diagnostic pathway. mpMRI combines multiple MRI sequences to identify suspicious areas within the prostate. Lesions are reported using the PI-RADS scoring system (1–5): PI-RADS 4 and 5 lesions have high probability of clinically significant cancer and should be biopsied. PI-RADS 3 lesions are equivocal; clinical judgment and biomarkers guide next steps. MRI-negative (PI-RADS 1–2) glands have a low probability of clinically significant disease.
The MRI images are fused in real-time with transrectal or transperineal ultrasound to allow precise needle targeting of suspicious MRI lesions (targeted cores) alongside systematic sampling of the whole gland (systematic cores). This combination detects more clinically significant cancers and fewer insignificant ones than systematic biopsy alone. Transperineal biopsy reduces the risk of post-biopsy infection to near zero compared to the transrectal route.
MRI of the penis — performed after pharmacological erection induction with intracavernosal prostaglandin — is the most accurate modality for determining depth of invasion into the corpus cavernosum or spongiosum. This is critical for staging and for planning whether organ-sparing surgery is feasible.
Bone scan and CT: Historically used for staging but reserved for high-risk disease (PSA >10, Grade Group ≥3, or suspected metastatic disease). PSMA PET/CT (Prostate-Specific Membrane Antigen PET) has largely replaced conventional staging imaging at experienced centers — it detects lymph node and bone metastases with significantly higher sensitivity and specificity and is now the preferred modality for staging high-risk and recurrent prostate cancer.
Germline (inherited) testing is recommended for men with metastatic prostate cancer, high-risk localized disease, family history of BRCA-related cancers, or Ashkenazi Jewish ancestry. Somatic (tumor) testing is performed on biopsy or surgical tissue to identify actionable mutations (BRCA1/2, ATM, CDK12, MMR deficiency/MSI) that predict response to PARP inhibitors, immunotherapy, or other targeted agents.
Staging uses a system called TNM — it describes how far the cancer has grown locally (T), whether it has reached nearby lymph nodes (N), and whether it has spread to other parts of the body (M). Your doctor will assign a clinical stage before any treatment, based on MRI, PSA, and biopsy findings. If you have surgery, a more accurate “pathological” stage is confirmed from the removed specimen.
| Stage | Technical meaning | What it means for you |
|---|---|---|
| T1 | Cancer not felt on exam; found on biopsy after an elevated PSA | The most common presentation. The cancer is entirely inside the prostate and too small to feel. Highly curable. |
| T2 | Cancer can be felt on exam but is still inside the prostate | Still entirely within the prostate. Surgery or radiation can cure the vast majority of men at this stage. |
| T3a | Cancer has grown just outside the prostate wall (but not into neighboring organs) | Locally advanced — the cancer has broken through the prostate’s outer layer. Radiation combined with hormone therapy is preferred for most men. Surgery is still appropriate for some younger, fitter patients. If T3a is found on the surgical specimen after a prostatectomy, it doesn’t automatically mean you need more treatment right away — your PSA trend guides next steps. |
| T3b | Cancer has grown into the seminal vesicles (glands just above the prostate) | Higher-risk locally advanced disease. Combined treatment — usually radiation plus longer-term hormone therapy — is standard. |
| T4 | Cancer has grown into nearby structures (bladder, rectum, or pelvic wall) | Very locally advanced. Requires intensive combined treatment. Still potentially controllable with the right approach. |
| N1 | Cancer found in nearby lymph nodes in the pelvis | The cancer has spread to pelvic lymph nodes. This is serious but not necessarily incurable — hormone therapy combined with radiation or surgery can still achieve long-term control in many men. |
After biopsy, your doctor combines your PSA level, Grade Group, and how far the cancer has grown to put you into one of six risk groups. This group determines how urgently you need treatment and how intensive that treatment should be. It’s the most practically important piece of information after your diagnosis.
The technical criteria are listed beneath each card — but the most important part is the plain-English summary of what each group means for your care.
What this means for you: Your cancer is the most indolent type possible. Studies show the vast majority of men with very low risk disease will never need treatment — and those who do will be caught early enough on surveillance that treatment will still be curative. Active surveillance is the strongly preferred approach. You do not need to rush into surgery or radiation.
Technical criteria (all must be met)
What this means for you: Very similar to very low risk — your cancer is low-grade and confined to the prostate. Active surveillance is still the preferred choice for most men. If you're older or have other health issues, you may never need any treatment at all. If you're younger and would prefer not to live with an untreated cancer, surgery or radiation are both excellent options.
Technical criteria (all must be met)
What this means for you: Your cancer has one feature that puts it above low risk — either a slightly elevated PSA, a Grade Group 2 (Gleason 3+4=7), or a slightly larger tumor on exam. The cancer is still curable, but a decision about active surveillance vs. treatment needs more careful thought. For men with Grade Group 2 and a low volume of cancer, surveillance remains a reasonable option; most men at this level will be recommended surgery or radiation.
Technical criteria
What this means for you: Your cancer has multiple risk features or a Grade Group 3 (Gleason 4+3=7) — meaning the more aggressive pattern makes up the majority. Active surveillance is not appropriate here. Definitive treatment — surgery or radiation — is recommended. If you choose radiation, a short course of hormone therapy (about 4–6 months) is usually added to improve results.
Technical criteria
What this means for you: Your cancer is aggressive and requires strong, combination treatment. This doesn't mean it's not treatable — many men with high-risk prostate cancer are cured. But it does mean you need more than one treatment working together. For most men, radiation combined with 18–36 months of hormone therapy is the preferred approach. Surgery is appropriate for select younger, fit patients. Additional medications (abiraterone or enzalutamide) alongside hormone therapy may further improve outcomes.
Technical criteria (any one)
What this means for you: This is the most intensive category for localized prostate cancer. Your cancer has spread to nearby structures or the biopsy shows the most aggressive patterns throughout. You'll need the most powerful combination of treatments — typically radiation plus long-term hormone therapy, sometimes with chemotherapy added. PSMA PET/CT imaging is strongly recommended to make sure the cancer hasn't already spread beyond the pelvis before starting treatment. Despite the intensity required, many men with very high risk disease are still cured or achieve long-term control.
Technical criteria (any one)
Beyond PSA, a growing number of blood tests, urine tests, and tissue tests can give more precise information about whether a biopsy is needed, how aggressive your cancer really is, and whether you can safely stay on active surveillance. These tests rarely change the diagnosis — but they often help you and your doctor feel more confident about a decision.
You don’t need to know all of them. But if your doctor mentions one, here’s what it means:
When your PSA is mildly elevated but not clearly alarming, these tests can refine the picture — helping avoid an unnecessary biopsy when risk is low, or prompting a biopsy when risk is higher than PSA alone suggests.
| Test | Sample | What it tells you | When your doctor might order it |
|---|---|---|---|
| PSA Density | Blood + MRI | Adjusts your PSA for the size of your prostate. A large prostate naturally produces more PSA — so a high PSA in a very large prostate is less concerning than the same PSA in a small prostate. | When your PSA is elevated but your prostate is also large; helps decide whether to biopsy |
| 4Kscore | Blood | Measures four proteins in your blood to predict the probability that a significant cancer (Grade Group 2 or higher) would be found on biopsy. Gives a percentage risk — e.g. “12% chance of significant cancer.” | PSA elevated in the 2–10 range; you and your doctor are deciding whether a biopsy is needed |
| PHI (Prostate Health Index) | Blood | Uses different forms of PSA to more accurately distinguish between BPH (enlarged prostate) and cancer. A low PHI suggests the PSA rise is likely from BPH, not cancer. | Similar to 4Kscore — helps decide whether to biopsy when PSA is mildly elevated |
| ExoDx / MPS2 | Urine | Detects genetic material shed by prostate cancer cells into urine. Provides additional risk information about whether a significant cancer is likely to be found. | As an adjunct to PSA and MRI when refining the biopsy decision |
After a biopsy confirms cancer, these genomic tests analyze the genetic activity of the cancer cells to answer a crucial question: is this cancer as aggressive as the Gleason score suggests, or is it more (or less) dangerous than it looks? They're most useful when you're deciding between active surveillance and treatment, or between treatment options.
| Test | What it measures | What it helps you decide |
|---|---|---|
| Oncotype DX (Genomic Prostate Score) | Activity of 17 cancer-related genes in your biopsy | If you have Grade Group 1 or 2 cancer and are considering active surveillance, a low GPS score provides reassurance that the cancer is truly indolent. A high score suggests it may be more aggressive than it looks. |
| Decipher | Activity of 22 genes; predicts risk of the cancer spreading | Useful both after biopsy (for intermediate/high-risk patients deciding on treatment) and after prostatectomy (to decide whether adjuvant radiation is needed). A high Decipher score means you’d benefit from more aggressive treatment; a low score may allow de-escalation. |
| Prolaris | How fast cancer cells are dividing (cell cycle genes) | Refines prognosis for low-to-intermediate risk cancer — helps confirm whether active surveillance is safe or treatment is needed sooner. |
These are different from the tissue tests above — they look at genes in your blood (inherited from your parents) rather than genes in the tumor itself.
checks whether you were born with a mutation — like BRCA2 — that both increases cancer aggressiveness and makes certain treatments more effective (particularly PARP inhibitors like olaparib). It's recommended for all men with metastatic prostate cancer, high-risk localized disease, a strong family history of prostate or breast cancer, or Ashkenazi Jewish ancestry. A positive result also has implications for your children and siblings — genetic counseling is offered alongside testing.
Almost certainly not. Most men with low-risk prostate cancer won't need any of the genomic tests. Your doctor will recommend specific tests based on your situation. The key thing to know is that these tests exist — so if you're unsure whether active surveillance is safe, or whether a particular treatment is worth its side effects, ask Dr. Bansal whether a genomic test might help clarify the decision.
Treatment selection depends on risk group, PSA level, Grade Group, clinical stage, patient age, baseline urinary and sexual function, comorbidities, and personal preferences. For many men, more than one treatment approach is clinically equivalent — making shared decision-making between patient and physician essential.
Active surveillance (AS) is not “doing nothing” — it is a structured monitoring strategy that defers treatment until (and unless) there is evidence of disease progression. It is the preferred management for very low- and low-risk prostate cancer, and is appropriate for selected men with favorable intermediate-risk disease (Grade Group 2, low volume).
Men with Grade Group 1 (Gleason 6) prostate cancer who have a life expectancy less than 20 years can reasonably expect to die of something other than their prostate cancer if managed with AS. Men with low-volume Grade Group 2 (Gleason 3+4=7) may also be managed on AS at experienced centers with close follow-up and genomic testing to confirm indolent biology.
A typical AS protocol includes PSA testing every 3–6 months, digital rectal exam annually, repeat prostate MRI at 1 year and then every 2–3 years, and repeat prostate biopsy (with MRI/ultrasound fusion) at 1–2 years and periodically thereafter. Conversion to active treatment is recommended if Grade Group increases to 3 or above, PSA doubles rapidly, MRI shows significant progression, or the patient's preference changes.
Multiple large prospective cohorts (UCSF, Johns Hopkins, Toronto) and the randomized ProtecT trial have confirmed that properly selected men on AS have prostate cancer-specific survival exceeding 99% at 10–15 years, comparable to immediate treatment.
Low Oncotype DX GPS or Decipher scores provide additional confidence in the AS decision. A high genomic score in a Grade Group 1 patient should prompt reconsideration of the approach.
Radical prostatectomy — surgical removal of the prostate gland and seminal vesicles, plus a pelvic lymph node dissection when indicated — is one of the two primary curative treatments for localized and locally advanced prostate cancer. At Bansal Urology, radical prostatectomy is performed using robotic assistance (da Vinci system), which provides superior visualization, precision, and minimally invasive access through 5–6 small port sites.
The neurovascular bundles running along the posterolateral surface of the prostate are responsible for erectile function. When tumor margins allow, nerve-sparing dissection preserves one or both bundles, significantly improving the probability of erectile function recovery. The decision to spare, partially spare, or excise the nerve bundle depends on tumor location, Grade Group, and PSA — assessed by the surgeon intraoperatively with input from preoperative MRI.
Provides definitive pathological staging (pT stage, margin status, lymph node assessment) that refines prognosis.
PSA drops to undetectable (<0.1 ng/mL) within weeks if surgery is successful — providing immediate biochemical feedback.
Radiation and ADT remain available as salvage options if cancer recurs after surgery.
Preferred for younger men, those with urinary obstruction, or those with large prostates poorly suited to radiation.
Urinary incontinence is common in the first weeks-to-months after surgery. Most men regain continence by 6–12 months; a small percentage require further intervention.
Erectile dysfunction is expected immediately post-operatively; recovery depends on age, baseline function, and nerve-sparing status. Penile rehabilitation (PDE5 inhibitors, vacuum devices) aids recovery.
Positive surgical margins or adverse pathological features trigger consideration of adjuvant or salvage radiation therapy.
A pelvic lymph node dissection (PLND) is recommended for men with intermediate-high to high-risk disease. An extended PLND (ePLND) — covering the obturator, external iliac, and internal iliac regions — is preferred over limited dissection for accurate staging. Lymph node positivity (pN1) triggers discussion of adjuvant ADT with or without radiation.
Radiation therapy achieves equivalent long-term cancer control to radical prostatectomy for most risk groups of localized prostate cancer and is the preferred treatment for locally advanced (T3–T4) disease when combined with ADT. Two primary modalities are used, often in combination.
Most common radiation modality
Intensity-modulated radiation therapy (IMRT) with image guidance (IGRT) delivers highly conformal radiation to the prostate while limiting dose to the rectum and bladder. Typically 20–28 daily fractions (4–6 weeks) in moderate hypofractionation protocols, or 5 fractions with stereotactic body radiation (SBRT/SABR) in ultra-hypofractionation.
SBRT (5 fractions over 2 weeks) for localized prostate cancer is supported by Phase 3 trials (PACE-B) and is increasingly standard for low- and intermediate-risk disease — achieving equivalent cancer control with dramatically reduced treatment burden.
Internal radiation
LDR brachytherapy (seed implant): Radioactive seeds (iodine-125 or palladium-103) are permanently implanted into the prostate under ultrasound guidance. Excellent cancer control for low- and favorable intermediate-risk disease. Performed as an outpatient procedure in 1–2 hours.
HDR brachytherapy (temporary implant): High-dose rate catheters deliver a few large radiation fractions. Often combined with EBRT for high-risk disease. Highly conformal dose distribution with rapid dose falloff outside the prostate.
For unfavorable intermediate-risk disease: short-term ADT (4–6 months) added to radiation improves biochemical control and survival. For high-risk and very high-risk disease: long-term ADT (18–36 months) is standard of care with radiation. For very high-risk disease, consideration of abiraterone or enzalutamide added to ADT + radiation is supported by randomized data (STAMPEDE, ATLAS).
Men with a rising PSA after radical prostatectomy (biochemical recurrence, BCR) are candidates for salvage radiation to the prostate bed. Early salvage radiation — when PSA is still very low (0.2 ng/mL or adverse pathological features.
Focal therapy targets only the index lesion (the dominant cancer focus) within the prostate, leaving the remainder of the gland untreated. It occupies a middle ground between active surveillance (no treatment) and whole-gland therapy (surgery or radiation) — offering cancer control with the best potential for preservation of urinary and sexual function. Dr. Bansal is experienced in focal therapy techniques and uses precision imaging to select appropriate candidates.
Focal therapy is most appropriate for men with: localized prostate cancer (organ-confined, no metastases); Grade Group 1–3 (Gleason 6–4+3=7); a tumor visible and well-delineated on mpMRI; unilateral or predominantly unilateral disease; and a desire to preserve urinary and sexual function. Bilateral disease and high-volume Grade Group 3 are relative contraindications.
| Feature | HIFU | Cryotherapy | IRE (NanoKnife) |
|---|---|---|---|
| Mechanism | Focused ultrasound heat (80–100°C) | Freeze-thaw cycles (−40°C) | Electrical pulses disrupt cell membranes |
| Guidance | MRI-guided or ultrasound-guided | Ultrasound-guided | Ultrasound-guided |
| Anesthesia | General or spinal | General or spinal | General (neuromuscular blockade required) |
| Hospital stay | Outpatient | Outpatient | Outpatient |
| Mechanism | Focused ultrasound heat (80–100°C) | Freeze-thaw cycles (−40°C) | Electrical pulses disrupt cell membranes |
| Nerve preservation | High — heat boundary is precise | Moderate — ice ball must avoid neurovascular bundle | Very high — non-thermal; preserves adjacent structures |
| Re-treatment | Yes | Yes | Yes |
PSA is monitored every 3–6 months. A PSA nadir is typically reached 3–6 months after treatment. mpMRI is performed at 6–12 months to assess treatment response. Prostate biopsy (fusion-targeted) is performed at 6–12 months and then annually or as guided by PSA/MRI findings. Men who fail focal therapy can proceed to whole-gland treatment (surgery or radiation) without having "burned any bridges."
While functional outcomes (continence and erectile function preservation) are excellent with focal therapy, long-term randomized data comparing focal therapy to surgery or radiation for cancer control are still maturing. Focal therapy is offered at Bansal Urology within the framework of shared decision-making with clear disclosure of the available evidence.
Prostate cancer cells need testosterone to grow. Hormone therapy — also called androgen deprivation therapy or ADT — works by reducing testosterone in the body to very low levels, starving the cancer of the fuel it needs. It doesn’t cure prostate cancer on its own, but when combined with radiation for high-risk disease, or used to control metastatic cancer, it significantly improves survival and slows progression.
ADT is not something most men look forward to — its side effects are real and wide-ranging. But understanding what to expect makes them easier to manage, and many of them can be substantially reduced with the right strategies.
LHRH agonists — leuprolide, goserelin
Given as a monthly, 3-monthly, or 6-monthly injection under the skin or into a muscle. They work by initially causing a brief surge in testosterone (called a “flare”) before shutting it down. The flare typically lasts 1–2 weeks and can temporarily worsen bone pain in men with bone metastases — which is why a short course of antiandrogen tablets is given at the same time to block the flare’s effect.
Most men receiving injections get their testosterone to very low levels within 3–4 weeks of the first dose.
LHRH antagonists — relugolix (Orgovyx), degarelix
These work differently — they immediately block testosterone without the initial flare. Relugolix (brand name Orgovyx) is a once-daily pill, which many men prefer to injections. Studies suggest it may have a lower risk of cardiovascular side effects compared to the injection form — making it particularly worth discussing if you have heart disease or high blood pressure.
Degarelix is given as a monthly injection and also works without a flare.
These are the effects of having very low testosterone, not the drug itself. Most men experience some of them; few experience all:
| Side effect | How common | What actually helps |
|---|---|---|
| Hot flashes | Very common (50–80%) | Venlafaxine, medroxyprogesterone, or gabapentin prescribed by your doctor; some men find acupuncture helpful |
| Loss of sex drive (libido) | Very common | Normal consequence of low testosterone; discuss impact on relationship with partner; testosterone recovers after short-term ADT ends |
| Erectile dysfunction | Very common | PDE5 inhibitors (Viagra, Cialis) can help partially; penile rehabilitation program discussed with Dr. Bansal |
| Fatigue | Common | Regular aerobic exercise — even walking 30 minutes daily — is the most evidence-based intervention |
| Muscle loss & weight gain | Common over months | Resistance training (weights or resistance bands) twice weekly preserves muscle mass significantly |
| Bone thinning (osteoporosis) | Builds gradually | Bone density scan (DEXA) at baseline and periodically; calcium + vitamin D; weight-bearing exercise; bone-protecting medications (denosumab, bisphosphonates) if indicated |
| Mood changes / depression | Moderate | Exercise helps; mention to your doctor if significant — treatment is available |
| Cognitive “brain fog” | Some men | Usually mild; puzzle and memory exercises may help; usually improves after short-term ADT ends |
This depends entirely on your risk group and treatment plan. For intermediate-risk disease with radiation: typically 4–6 months. For high-risk disease: 18–36 months alongside radiation. For metastatic disease: usually ongoing, indefinitely. For men on short-term ADT alongside radiation, testosterone typically recovers within 6–18 months after stopping — and most side effects reverse with it.
For men with non-metastatic disease, ADT can sometimes be given in planned cycles — on for several months, then off to allow testosterone to recover — rather than continuously. This gives your body (and quality of life) a break during the off period. It's not suitable for all patients, but worth asking about if long-term ADT is proposed and you're concerned about the side effects.
Precision Treatment. Preserved Function. Faster Recovery.
Focal therapy is a minimally invasive treatment for men with localized, low- to intermediate-risk prostate cancer. Unlike traditional treatments that affect the entire prostate gland, focal therapy targets only the cancerous area, preserving healthy tissue and reducing side effects. It offers a balance between effective cancer control and maintaining quality of life.
You may be a candidate for focal therapy if:
We use the latest imaging and diagnostic technologies to precisely locate and assess the tumor, including:
Based on your cancer’s characteristics, we offer the following focal therapy techniques:
Prostate cancer prognosis is strongly linked to stage and Grade Group at diagnosis. The vast majority of men diagnosed with localized prostate cancer will not die of their disease. For metastatic disease, outcomes have improved dramatically — but long-term cure remains uncommon.
| Stage / Risk Group | 5-Year Survival | 10-Year PCa–Specific Survival | Notes |
|---|---|---|---|
| Very low / Low risk (localized) | >99% | >99% | Most men die of competing causes; AS is preferred |
| Favorable intermediate risk | >99% | >98% | Excellent outcomes with definitive treatment; AS possible for selected GG2 |
| Unfavorable intermediate risk | >99% | ~95% | Definitive treatment required; short-term ADT with radiation |
| High / Very high risk (localized) | >95% | ~85–90% | Combined modality treatment; long-term ADT; consider abiraterone addition |
| Locally advanced / Node-positive | ~85% | ~60–70% | ADT + radiation or surgery; adjuvant ADT post-surgery for pN1 |
| Metastatic (mHSPC) | ~40–50% | ~20–30% | Improving with intensified upfront therapy (triplet regimens); median OS now approaching 5+ years with modern treatment |
A rising PSA after definitive treatment (biochemical recurrence) does not necessarily mean the cancer has spread. Many men with BCR after surgery or radiation live for decades without clinical metastases, particularly with low-grade disease and slow PSA doubling time.
These are population-level estimates. Individual prognosis depends on many factors including Grade Group, PSA kinetics, genomic risk scores, and response to treatment.
Whether you’re seeking expert care for a urological condition or looking for a second opinion, we’re here to support you every step of the way. Reach out to schedule an appointment, ask questions, or learn more about personalized, minimally invasive treatment options tailored to your needs.
